Page 194 - Eceptor News Today

Three subtypes of cancer-associated fibroblasts (CAF) could guide the design of personalized treatment for lung cancer patients, according to a new study in Cancer Cell led by researchers at Massachusetts General Hospital.

Researchers in the United States have conducted a study showing that Moderna’s coronavirus disease 2019 (COVID-19) vaccine provided durable protection against the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques.

The Delta variant of SARS-CoV-2 has swept the globe, becoming the dominant variant within just a few months. A new study from Boston Children's Hospital, published today in Science, explains why Delta is so easily spread and infects people so quickly, and suggests a more targeted strategy for developing future COVID-19 vaccines and treatments.

A Ludwig Cancer Research study has identified a means by which cancer cells engineer the conversion of immune cells known as macrophages from destroyers of tumors to supporters of their growth and survival.

Researchers from Oregon State University have developed a system to assess the ability of SARS-CoV-2 to bind to ACE2 orthologs.

A new study aimed to determine whether ACE2 targeting drugs change the tissue levels of ACE2 in healthy mice.

Men with Stage IV breast cancer and known estrogen (ER) and progesterone receptor (PR) status benefit from surgical intervention and from trimodal therapy (systemic therapy, surgery, and radiation), according to a study presented at the virtual American College of Surgeons (ACS) Clinical Congress 2021.

Researchers have been investigating the changes in receptor binding in these variants that increase the danger they pose.

Researchers isolated single cells among individuals with and without prior infection with the SARS-CoV-2 vaccinated with BNT162b2 mRNA vaccine and compared the nature of the neutralizing antibody response against the original Wuhan virus and the subsequent variants.

News-Medical speaks to Professor Tomohiro Kurosaki about how he has developed a new vaccine approach that could prevent future pandemics.